Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a ...

NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...

Emma Slade-Jones introduces the newly published guidance on medical conditions that may impact dental appointments.

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

will be highlighted in an oral presentation. In addition, a trial-in-progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic ...

“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming ...

Chief Scientific Officer, H2Ocean; Dr. Anita Kinney (M), President, American Society of Preventive Oncology; Eddie Kolos (R), ...

Pfizer advances bold vision for future of cancer care at the ASCO 2025 annual meeting: New York Friday, April 25, 2025, 10:00 Hrs [IST] Pfizer Inc. will showcase data across its p ...

announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal ® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be ...